Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer

CompletedOBSERVATIONAL
Enrollment

36

Participants

Timeline

Start Date

January 1, 2015

Primary Completion Date

February 1, 2022

Study Completion Date

April 1, 2023

Conditions
Thyroid Neoplasms
Interventions
RADIATION

Iodine-125 brachytherapy

"In advance of the surgery, patients were informed about their condition, the expected efficacy of 125I seed implantation therapy, alternative treatments such as external beam radiotherapy and chemotherapy, as well as potential side effects and toxic effects. The preoperative evaluation process includes assessments of coagulation function, liver and kidney function, cardiopulmonary function, and local CT scans.~A collaborative effort between physicians and physicists was undertaken to establish a treatment regimen with a prescription dose ranging from 80 to 120 Gy. The patient accepted the treatment plan and signed an informed consent form. The CT-guided 125I seed implantation procedure was conducted according to the prescribed treatment regimen.~Efficacy evaluations were conducted at pre-surgery, 1-, 3-, and 5-month post-surgery. The evaluations focused on lesion dimensions, serum Tg, TGAb, TSH levels, pain levels, and adverse reactions."

All Listed Sponsors
lead

Jiangxi Provincial Cancer Hospital

OTHER

NCT06362772 - Clinical Efficacy of 125I Seed Implantation in the Treatment of Refractory Differentiated Thyroid Cancer | Biotech Hunter | Biotech Hunter